Fundz

Aravive Announces $10.0 Million Investment By Eshelman Ventures, Llc And Appointment Of Dr. Eshelman As Executive Chairman Of The Aravive Board Of Directors

PRIVATEJan 03, 2022

Amount Raised

$10 Million

Round Type

Venture

HoustonBiotechnology

Description

Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the company’s Chairman, Fred Eshelman, Pharm.D., through Eshelman Ventures, LLC, agreed to purchase a pre-funded warrant to purchase 4,545,455 shares of the company’s common stock at a price of $2.20 per share, which was the consolidated closing bid price of the company’s common stock on The Nasdaq Global Select Market on December 31, 2021. The investment strengthens the company’s balance sheet by approximately $10.0 million, enhancing the company’s financial flexibility and liquidity ahead of multiple anticipated clinical milestones throughout 2022 for each of the company’s clinical programs. The investment is expected to close on January 5, 2022.

Quick answer

Aravive Biologics, Inc. raised $10 Million in a funding round, dated January 3, 2022. Aravive Biologics, Inc. is based in Houston, Texas, United States.

How much did Aravive Biologics, Inc. raise?
Aravive Biologics, Inc. raised $10 Million in a funding round on January 3, 2022.
What does Aravive Biologics, Inc. do?
Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies.
Where is Aravive Biologics, Inc. based and how big is it?
Aravive Biologics, Inc. is based in Houston, Texas, United States.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Aravive Biologics, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Synthego Corp raised $200M (Funding Round) on February 17, 2022.
  • Confluent Medical raised an undisclosed amount on February 17, 2022.
  • Seer raised $15M (Series B) on February 17, 2022.
  • Neo Medical raised $21M (Funding Round) on February 17, 2022.
  • Classiq raised $33M (Funding Round) on February 17, 2022.
  • Rubi Laboratories raised $4.5M (Seed) on February 17, 2022.

Who to call at Aravive Biologics, Inc., and when

A new round usually means Aravive Biologics, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Aravive Biologics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Aravive Biologics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Aravive Biologics, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Aravive Biologics, Inc.

Location

3730 KIRBY DRIVE

Houston, Texas, United States

About

Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival. Our technology, originated in the laboratories of Drs. Amato Giaccia and his colleagues at Stanford University, uses genetic screening to identify critical targets for the development of therapeutic molecules for cancer therapy while sparing healthy cells. This strategy is designed to enable us to interrupt oncogenic signals and, using our high-affinity decoy receptors, outcompete cancer’s ability to grow, metastasize and acquire resistance to treatments. We believe our unique cancer therapies may hold promise as a monotherapy or in combination with other cancer treatments, augmenting the anti-tumor activity of radiotherapy, chemotherapy, immuno-therapeutics and cancer vaccines. By targeting advanced or metastatic disease, our approach has the potential to significantly improve survival rates while simultaneously reducing toxicity in cancer patients.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Aravive Biologics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Aravive Biologics, Inc.'s next move

See what Strategic adds

Aravive Biologics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.